Carrick Therapeutics has an ambitious, patient-focused vision to serve cancer patients around the world through the introduction of ground-breaking therapies that will transform how the disease is treated. After assembling a world-class group of cancer researchers and drug development experts, Carrick needed to raise capital to make its mission a reality.
As a unique new venture in cancer treatment, Carrick Therapeutics was in search of a group of investors who shared their aspiration. The consortium was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, GV (Google Ventures), and Lightstone Ventures – each with strong track records of accelerating the development of cutting-edge science into new therapies. The Goodwin team helped Carrick execute on this groundbreaking transaction by combining our extensive experience in early-stage life sciences venture capital financings with our expertise in cross-border transactions.
By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will drive its portfolio of ground-breaking cancer therapies from laboratory to clinic. With an initial financing round generating $95 million of investments, Carrick hopes to begin building Europe’s leading oncology company. The infusion of capital allows Carrick to pursue its goal of developing a portfolio of unique first-in-class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumor.